Found 1 Presentation For Request "753P"
753P - Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME
- Sarah Missel (Munich, Germany)
Abstract
Background
T cell engaging bispecifics redirecting T cells towards human leukocyte antigen (HLA)-presented peptides are emerging as promising treatment modality for patients with solid tumors. We have developed bispecific T cell engaging receptor (TCER
Methods
After systematic evaluation, a TCR with high avidity and specificity towards the PRAME target peptide was selected for affinity maturation via yeast surface display resulting in more than 1,000-fold increased binding affinity while retaining specificity. The maturated TCR was then incorporated into our TCER® format.
Results
IMA402 showed
Conclusions
Upon preclinical proof-of-concept for the novel bispecific T cell engager IMA402 GMP manufacturing was initiated and is currently ongoing. IMA402 directed against PRAME will be the second TCER® entering clinical development with start of the phase 1 basket trial in several solid tumor indications planned for 2023.
Legal entity responsible for the study
Immatics Biotechnologies GmbH.
Funding
Immatics Biotechnologies GmbH.
Disclosure
S. Missel: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. S. Bunk: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. M. Hofmann: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. G. Pszolla: Financial Interests, Full or part-time Employment: Bayer AG. M. Hutt: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. F. Schwoebel: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. F. Unverdorben: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. C. Wagner: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. M. Jaworski: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. H. Schuster: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. F. Schwoerer: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. C. Schraeder: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. O. Schoor: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. T. Weinschenk: Financial Interests, Full or part-time Employment: Immatics N.V.. D. Maurer: Financial Interests, Full or part-time Employment: Immatics Biotechnologies GmbH. C. Reinhardt: Financial Interests, Full or part-time Employment: Immatics N.V.; Other, Member of the Board of Directors: Revitope Oncology Inc., Theolytics.